Undisclosed CAR-T / Oswaldo Cruz Foundation, Caring Cross - LARVOL DELTA

Fiocruz and Caring Cross Announce Collaboration Agreement to Enable Access to Affordable CAR-T Therapy in Brazil and Latin America (GlobeNewswire) - "Fundação Oswaldo Cruz (Fiocruz), a foundation from the Brazilian government's Ministry of Health, and Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to advanced medicinal cures for all patients, everywhere, today announced a collaboration to develop local manufacturing of chimeric antigen receptor (CAR)-T cell and stem cell gene therapies for oncology, infectious, and genetic diseases in Brazil, including CAR-T cell therapies for leukemia, lymphoma, and HIV infection...Under the terms of the agreement, Caring Cross will provide technology, materials, and training to the Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz) for the manufacture of CAR-T cell therapies and lentiviral vectors aimed for clinical development and approval."

Licensing / partnership • Hematological Malignancies • Human Immunodeficiency Virus • Leukemia • Lymphoma • Oncology